Home » Clinical Trials » Inherited retinal dystrophy » NCT04945772
NCT04945772

A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

Study Summary

The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).

Want to learn more about this trial?

Request More Info

Interventions

Gene Therapy Product-MCO-010BIOLOGICAL
The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
Sham InjectionPROCEDURE
Sham Injection

Study Locations

FacilityCityStateCountry
Nanoscope Clinical SiteBeverly HillsCaliforniaUnited States
Nanoscope Clinical SitePensacolaFloridaUnited States
Nanoscope Clinical SiteFargoNorth DakotaUnited States
Nanoscope Clinical SiteHoustonTexasUnited States
Nanoscope Clinical SiteMcAllenTexasUnited States
Nanoscope Clinical SiteAreciboPuerto Rico

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026